Today: 15 May 2026
SCHD ETF Nears Highs as Dividend Trade Revives and Early Investors Reach 12.5% Yield on Cost
20 April 2026
2 mins read

SCHD ETF Nears Highs as Dividend Trade Revives and Early Investors Reach 12.5% Yield on Cost

NEW YORK, April 20, 2026, 1:35 PM EDT

  • SCHD hovered around $31.06 on Monday, not far from its 52-week peak, with TipRanks projecting a gain of about 14% by 2026.
  • U.S. dividend funds brought in $24.1 billion in first-quarter inflows, Reuters reported, with SCHD alone pulling in close to $4 billion.
  • The fund shows a 3.33% 30-day SEC yield and a trailing distribution yield at 3.44%, with net assets standing at $87.5 billion, according to Schwab.

The Schwab U.S. Dividend Equity ETF hovered at $31.06 around midday Monday, holding near its 52-week peak after renewed analyst coverage drew attention to a standout dividend play this year. SCHD has climbed roughly 14% year to date, according to TipRanks.

It’s relevant at this point, with investors returning to dividend strategies while the S&P 500 and Nasdaq notch fresh records and oil prices continue to stoke inflation concerns. U.S. dividend income funds raked in $24.1 billion during the first quarter—best opening since 2020—according to Reuters, and SCHD saw inflows of roughly $4 billion.

The long-term picture got a boost Monday. TheStreet pointed out that anyone who picked up SCHD at its 2011 debut is pocketing about a 12.5% yield on cost—meaning annual cash returns compared to what they originally paid.

That tally lines up with Schwab’s reported distributions: the most recent four quarters returned $1.0557 per share. TheStreet pointed to a split-adjusted launch price near $8.47. Schwab, for its part, confirmed that the October 2024 3-for-1 share split left total shareholder value intact.

Fresh investors aren’t getting that income rate now. Schwab notes SCHD follows the Dow Jones U.S. Dividend 100 Index, with 104 holdings and a 0.06% expense ratio. The 30-day SEC yield stood at 3.33% as of April 16, while the trailing distribution yield landed at 3.44% as of March 31.

As of April 17, the fund counted Texas Instruments, UnitedHealth, Merck, Chevron, Coca-Cola, and PepsiCo among its biggest positions. According to a Seeking Alpha breakdown from the same day, the fund’s annual rules-driven shakeup has put more weight on energy, consumer staples, and healthcare stocks heading into 2026.

Bryan Armour at Morningstar describes SCHD as taking a “sensible, transparent, and risk-conscious approach.” He expects it to outperform the Russell 1000 Value Index on a risk-adjusted basis over the long haul. TheStreet

Jun Li, who leads global and Americas wealth and asset management at EY, notes that investors are turning to dividend strategies—aiming to strike a balance between income and exposure to equities. For Shanon Davis, chief executive at American Alternative Assets, dividends have stepped in as a kind of partial bond replacement.

The fund is up against plenty of competition. By the end of March, Vanguard’s Dividend Appreciation ETF managed $117.1 billion in assets, while Vanguard High Dividend Yield ETF held $88.8 billion. BlackRock’s iShares Core Dividend Growth ETF, as of April 17, reported $39.4 billion.

SCHD’s approach isn’t without its pitfalls. Seeking Alpha flagged that the fund’s heavy sector concentrations make it vulnerable to specific risks, while Reuters pointed out that oil hovering near $85 a barrel may keep both inflation and Treasury yields elevated—conditions that could weigh on equities generally. If oil prices drop or capital snaps back into megacap tech, SCHD could end up on the wrong side of the trade.

SCHD isn’t budging so far, with earnings season ramping up. Tesla, Boeing, Intel, and Procter & Gamble all have reports on deck this week, according to Reuters. That run of results could signal if the rally widens or flips back to favor growth stocks. Notably, Procter & Gamble sits among SCHD’s top 10 holdings.

Stock Market Today

  • Wheat Prices Decline Amid Weak Trade News and Lower Yields
    May 15, 2026, 11:00 AM EDT. Wheat futures fell on Friday morning across major U.S. exchanges following weak signals from the Trump-Xi meeting regarding agricultural purchases. Chicago SRW and Kansas City HRW wheat futures dropped between 9 and 20 cents. The Kansas Wheat Quality Tour reported an average yield of 38.9 bushels per acre, the lowest since 2023, pushing production estimates slightly higher than USDA projections. USDA export sales showed robust old crop demand, particularly from Indonesia and the Philippines, though new crop sales were significantly down year-on-year. Market watchers cite weak trade developments and yield concerns as key factors driving the early losses in wheat prices.

Latest articles

Plug Power Stock Drops Again: The $5 Billion Hydrogen Turnaround Faces Its Cash Test

Plug Power Stock Drops Again: The $5 Billion Hydrogen Turnaround Faces Its Cash Test

15 May 2026
Plug Power shares fell 1.7% to $3.725 in early Nasdaq trading Friday, following a volatile week after first-quarter results. The company reported a 22% revenue increase to $163.5 million and improved gross margin, but its net loss widened to $245.3 million and operating cash use rose to $150 million. Plug ended March with $802 million in cash and expects $142 million from a hydrogen asset sale in June.
Why Ford Motor Company Stock Is Sliding After Its AI Data Center Rally

Why Ford Motor Company Stock Is Sliding After Its AI Data Center Rally

15 May 2026
Ford shares dropped 7% to $13.43 in early Friday trading, reversing part of a rally sparked by the launch of its new Ford Energy unit. The subsidiary, announced this week, will sell large battery energy storage systems to utilities and data centers, with first deliveries expected in late 2027. CEO Jim Farley said Ford is in the contracting phase with several customers. The stock had surged 13% Wednesday after Morgan Stanley highlighted the business.
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

15 May 2026
Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
Nokia Oyj Stock Pulls Back After AI Rally: What Investors Need to Know

Nokia Oyj Stock Pulls Back After AI Rally: What Investors Need to Know

15 May 2026
Nokia’s U.S.-listed shares dropped about 5% Friday, trading at $13.74 after a recent AI-driven surge. The decline followed a rally sparked by Cisco’s report of $5.3 billion in AI infrastructure orders from hyperscalers. Nokia saw a 54% jump in first-quarter operating profit and named Siemens’ Emma Falck as president of Mobile Infrastructure, effective September 1.
US Stock Market Today: S&P 500, Nasdaq Slip From Records as Oil Spike Tests Wall Street Rally
Previous Story

US Stock Market Today: S&P 500, Nasdaq Slip From Records as Oil Spike Tests Wall Street Rally

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset
Next Story

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Go toTop